Ingrezza costs roughly $8,000 to $8,700 for a 28-day supply without insurance, translating to an annual price between $103,000 and $113,000. That makes it one of the more expensive brand-name medications on the market, and the price comes down to a combination of limited competition, long-lasting patent protection, a small patient population, and the high cost of developing a first-in-class drug.
What a Month of Ingrezza Actually Costs
At cash prices, a 28-day supply of the 40 mg capsule runs about $7,921, while the 80 mg strength costs around $8,702. That breaks down to $282 to $310 per capsule. Most people taking Ingrezza don’t pay these full amounts because insurance, copay programs, or patient assistance absorb a large share of the cost. But these list prices are what drive up premiums and out-of-pocket expenses across the system.
A Small Market With Few Alternatives
Ingrezza treats tardive dyskinesia, a movement disorder caused by long-term use of certain psychiatric medications. It was the first drug the FDA approved specifically for this condition, reaching the market in 2017. The population of people with tardive dyskinesia is relatively small compared to conditions like high blood pressure or diabetes, which means the manufacturer needs to recoup its investment across far fewer patients. That basic math pushes per-patient costs higher.
There is one direct competitor: Austedo XR, which costs about $7,226 for a 28-day supply. The two drugs are priced within roughly 10% of each other, so there’s no real price pressure forcing either one down. When only two branded products serve an entire market and neither faces generic competition, prices stay elevated. In 2023, Ingrezza also received FDA approval for chorea associated with Huntington’s disease, broadening its patient base slightly, but both conditions remain relatively uncommon.
Patent Protection Lasts Until 2040
One of the biggest reasons Ingrezza will stay expensive for years is its patent portfolio. The last qualifying patent on valbenazine (the active ingredient) doesn’t expire until August 2040. That gives Neurocrine Biosciences, the manufacturer, roughly 15 more years of market exclusivity for its branded product.
On top of standard patent protection, Ingrezza received orphan drug designation from the FDA for treating Huntington’s chorea. Orphan drug status grants seven years of marketing exclusivity for that specific use, running through August 2030. This designation exists to encourage companies to develop treatments for rare diseases, but it also shields a portion of the drug’s market from competition even if another company developed an identical molecule.
While FDA records show that a first-to-file generic applicant received a commercial marketing date in early 2024, patent protections and ongoing litigation typically delay meaningful generic availability well beyond initial filings. Until generics actually reach pharmacies, the price won’t drop significantly.
The Cost of Developing a New Drug Class
Ingrezza wasn’t a minor tweak to an existing molecule. It was the first medication designed and approved specifically for tardive dyskinesia, a condition that previously had no FDA-approved treatment. Developing a first-in-class drug is significantly more expensive and risky than creating a variation of something that already works. Most compounds that enter clinical trials never make it to approval, and companies factor those failures into the price of the drugs that do succeed.
Neurocrine Biosciences spent $1.016 billion on research and development in its most recent fiscal year across all its programs, up from $565 million just two years earlier. The company doesn’t break out spending by individual drug, but Ingrezza is its flagship product and the primary revenue source funding that pipeline. The high price reflects not just what it cost to develop Ingrezza itself, but Neurocrine’s broader bet on neuroscience drugs that may or may not reach the market.
How Patients Reduce Out-of-Pocket Costs
Despite the sticker price, most patients taking Ingrezza pay substantially less. Neurocrine offers a Patient Assistance Program that provides the drug at no cost to people who are uninsured, lack prescription coverage, or meet certain financial criteria. For those with commercial insurance, copay assistance programs can reduce monthly costs to a fraction of the list price.
If you have insurance, your actual cost depends heavily on your plan’s formulary, your deductible, and whether Ingrezza falls under a specialty drug tier. Many insurance plans do cover it, but prior authorization is common, meaning your doctor will need to document that you’ve tried other approaches or that Ingrezza is medically necessary. Reaching out to Neurocrine’s access support line (1-84-INGREZZA) before filling a prescription can help you understand what you’ll actually owe and whether you qualify for financial help.
Why the Price Is Unlikely to Drop Soon
The conditions that keep Ingrezza expensive are all still in place: patent protection extending to 2040, only one competitor priced at a similar level, a relatively small patient population, and orphan drug exclusivity for one of its approved uses. Until generic versions of valbenazine become widely available or a new class of competitors enters the market, the annual cost will likely remain in the six-figure range at list price. For now, financial assistance programs are the most practical path to making the drug affordable on an individual level.